Abstract 186P
Background
Sorafenib is a multikinase inhibitor used to treat patients with unresectable hepatocellular carcinoma (HCC); however, there is no consensus on its efficacy in patients with HCC post hepatic resection. Therefore, this meta-analysis (PROSPERO ID: CRD42019122147) assessed efficacy and safety of sorafenib in patients with HCC who underwent hepatic resection.
Methods
Using PICO framework, relevant articles were retrieved from PubMed, EMBASE, Cochrane Library and Google Scholar. Articles comparing outcomes of sorafenib treated patients with HCC who underwent resection with those not receiving sorafenib were included for the analysis The primary outcome was overall survival (OS) while disease free survival (DFS), tumor recurrence rate (TRR), mortality and safety were the secondary outcomes. Hazard ratio (HR) or risk ratio (RR) along with 95% confidence interval (CI) were calculated by fixed or random effects (FE or RE) model, based on the heterogeneity. P < 0.05 was considered significant. The effect of portal vein tumor thrombosis (PVTT) and time of initiation of sorafenib therapy on survival were assessed by subgroup analysis.
Results
A total of 10 studies with data of 589 patients (mean age 52.41 years; men: 87.28%; women: 12.72%) were included in the analysis. Sorafenib significantly prolonged OS (n = 5; FE; HR: 0.69; 95% CI; 0.52, 0.93; P =.0139), reduced TRR (n = 8; FE; RR: 0.91; 95% CI: 0.83, 0.98; P =.0187) and mortality (n = 7; FE; RR: 0.75; 95% CI: 0.63, 0.88; P =.0007) in patients with HCC following hepatic resection compared to the control group. Further, DFS in the sorafenib group was non-significantly better than the control group (n = 5; FE; HR: 0.78; 95% CI: 0.56, 1.09; P =.1462). Although, the proportion of adverse events (AEs) was higher in the sorafenib group (81.1% vs 18.9%), the AEs were tolerable. Subgroup analysis revealed sorafenib to be more effective (lower TRR and mortality) in patients without PVTT than those with PVTT.
Conclusions
Adjuvant sorafenib treatment improved survival outcomes in HCC patients post hepatic resection and had acceptable safety profile. Hence, sorafenib could be recommended as an adjuvant therapy for patients with HCC after hepatic resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Science Fund for Creative Research Groups, NSFC, China (81521091); State key infection disease project of China (2018ZX10732202-002-005); National Human Genetic Resources Sharing Service Platform (2005DKA21300);.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract